StemRIM Inc. (JP:4599)
:4599
Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥360.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥17.68B
Enterprise Value¥14.10B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Sep 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-31.14
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Near-zero DebtNear-zero debt materially reduces financial risk and gives the company durable flexibility to fund R&D, extend clinical programs, or pursue partnerships without immediate refinancing pressure. This structural balance sheet strength supports strategic options over the next 2–6 months.
Proprietary Regenerative Medicine PlatformOwning proprietary stem-cell activation and regeneration-inducing technologies creates a durable competitive moat in regenerative medicine. Platform IP increases attractiveness to pharma partners, enables licensing scalability, and supports longer-term commercialization pathways if clinical progress continues.
Licensing And Collaboration-based Revenue ModelA licensing and collaboration-centric business model provides multiple non-dilutive revenue levers—licensing fees, milestone payments, and partner-funded research—that can monetize R&D without immediate product commercialization. This structural model supports staged cash inflows as partnerships and milestones are achieved.
Bears Say
Revenue Disappearance And Volatile IncomeRevenue collapsing to zero and a swing from modest profit to multi-year losses sharply reduces visibility into core demand and operating scalability. Reliance on irregular or one-off receipts undermines durable top-line predictability and complicates planning for clinical and commercial investments.
Persistent Negative Operating And Free Cash FlowTwo consecutive years of deep negative operating cash flow and sustained negative free cash flow indicate structural cash burn. This forces reliance on existing balance sheet or external funding, increasing dilution or financing risk and limiting the firm's ability to self-fund trials and long-term development.
Eroding Equity / Shrinking Capital CushionSignificant equity erosion over two years reduces the capital buffer available to absorb further losses and fund development. Even with low debt, shrinking shareholders' equity weakens solvency headroom, constrains negotiating leverage with partners, and raises the stakes on achieving near-term funding or revenue milestones.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥360.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥17.68B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Sep 16, 2026 which is in 97 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Jun 10, 2026. The company reported -¥7.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.6.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥7.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.333%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---